6:24 PM
Feb 04, 2015
 |  BC Extra  |  Top Story

New China FDA chief signals pricing reform a priority

A change at the top of China FDA may indicate that drug pricing reform is now a top priority of the government.

China State Council Deputy Secretary-General Bi Jingquan will serve as both CFDA commissioner and secretary-general of the Communist Party, a minister-level position. Bi served for more than a decade at the powerful National Development and Reform Commission (NDRC), China's top economic planning agency under the State Council. In the pharma industry, NDRC is best known for oversight of drug pricing and enforcement of the Anti-Monopoly Law....

Read the full 425 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >